FDA 483 - Oklahoma Blood Institute - June 07, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Oklahoma Blood Institute - Sylvan N Goldman Center in Oklahoma City revealed significant deficiencies in quality control and record-keeping for blood and blood components. Observations included failures in documenting bacterial contamination testing, inadequate investigations of viral screening discrepancies, and improper donor medical history assessments. Additionally, issues were noted with maintaining concurrent records, performing required testing according to manufacturer instructions, and ensuring equipment was level and calibrated.
ID · 83a0b86a-7cf9-4d3b-a71f-745593b66c2e